Pay in 4 interest-free payments of $5.51 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
11 , e2201655 (2022)
No completed human clinical trials exist yet, though Phase 1 data for the analog CB4211 showed promising metabolic improvements
The feeling of being completely in the moment, effortlessly echoing the rhythms with an orchestra behind you, brings me indescribable joy
12 hours | Primary site of action: extracellular matrix, gene expression | Key receptors: TGF-beta, MMP/TIMP | Research focus: skin regeneration, anti-aging, collagen | Endogenous: yes (plasma component) | Gene modulation: over 4,000 genes BPC-157 Half-life: approx
Future dosing recommendations will likely change based on these results, making it worth following the peptide regulation news for updates
US$ 23.38
US$ 24.61
US$ 24.69
